In this episode of the Expose MASH [formerly NASH] podcast, Dr Mohammad Siddiqui (Professor of Medicine at Virginia Commonwealth University) is joined by Andrew Schreiner, MD (Physician at the Medical University of South Carolina) and Arthi Thirumalai, MBBS (Attending Physician at the University of Washington School of Medicine and Harborview Medical Center). Our experts discuss the barriers to early diagnosis in patients with MASLD/MASH, with a focus on the challenges and misconceptions that hinder widespread...
In this episode of the Expose MASH [formerly NASH] podcast, Dr Mohammad Siddiqui (Professor of Medicine at Virginia Commonwealth University) is joined by Andrew Schreiner, MD (Physician at the Medical University of South Carolina) and Arthi Thirumalai, MBBS (Attending Physician at the University of Washington School of Medicine and Harborview Medical Center). Our experts discuss the barriers to early diagnosis in patients with MASLD/MASH, with a focus on the challenges and misconceptions that hinder widespread screening. They will highlight small changes that can be implemented to help overcome these challenges to improve screening practices.
For more information about MASLD/MASH, click here
This program is intended for clinicians in the US only. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
Mohammad Siddiqui, MD
Professor of Medicine at Virginia Commonwealth University
Richmond, VA
Andrew Schreiner, MD
Physician
Medical University of South Carolina
Charleston, SC
Arthi Thirumalai, MBBS
Attending Physician
University of Washington School of Medicine and Harborview Medical Center
Seattle, WA
Click here for full reference list
References
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-1153.
Allen AM, Charlton M, Cusi K, et al. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgraduate Med. 2024;136(3):229–245.
Allen AM, Hoovler AR, Articolo A, Fisher T, Noureddin M, Dieterich D. Gaps in MASLD/MASH education: a quantitative and qualitative survey with leaders of US graduate medical education programs. Adv in Med Ed and Pract. 2025;16:729–748.
Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020;3(4):e001122.
Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care. 2025;25:1-26.
Cusi K, Budd J, Johnson E, Shubrook J. Making sense of the nonalcoholic fatty liver disease clinical practice guidelines: what clinicians need to know.
Diabetes Spectr. 2024;37(1):29-38.
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings. Endocr Pract. 2022;28(5):528-562.
Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;16(5):1547-1554.
Eskridge W, Cryer DR, Schattenberg JM, et al. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective. J Clin Med. 2023;12(19):6216.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.
Forlano R, Sigon G, Mullish BH, Yee M, Manousou P. Screening for NAFLD-current knowledge and challenges. Metabolites. 2023;13(4):536.
Godoy-Matos AF, Silva Junior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60.
Golabi P, Owrangi S, Younossi ZM. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis – prevalence, clinical impact, economic implications and management strategies. Alimentary Pharmacol & Ther. 2024;59(Suppl. 1):S1-S9.
Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne). 2021;8:615978.
Lionis C, Papadakis S, Anastasaki M, et al. Practice recommendations for the management of MASLD in primary care: consensus results. Disease. 2024;12(8):180. Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649-1659.
Piao C, Arteaga EJ, Chen S, et al. Improved detection of fibrotic nonalcoholic fatty liver disease in community-based referrals. Metab Syndr Relat Disord. 2023;21(9):475-478.
Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
Shroff H, VanWagner LB. Cardiovascular disease in nonalcoholic steatohepatitis: screening and management. Curr Hepatol Rep. 2020;19(3):315-326.
Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7): 696-703.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.
Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-1586.
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347.
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
Zhang L, Mao Y. Artificial intelligence in NAFLD: will liver biopsy still be necessary in the future? Healthcare (Basel). 2022;11(1):117.
